Establishing new more holistic methods to evaluate MS treatment outcomes The importance of early intervention was supported by the Biogen-sponsored CHAMPS (Controlled High-risk Avonex MultiPle ...

Celgene is to file its potential multiple sclerosis blockbuster ozanimod by the end of the year following phase 3 results showing it outperformed established injectable Avonex. Ozanimod was ...